Phibro Animal Health appoints Glenn C. David as CFO effective Feb 9, 2024

PHIBRO ANIMAL HEALTH CORP

Glenn C. David, former Zoetis CFO and group president, joins Phibro as CFO starting Feb 9, 2024.
David receives $650K base salary, 50% target bonus, $135K signing bonus, and 300K RSUs (half time-vesting, half performance-vesting).
Performance RSUs vest based on 90-day average stock price from $20 to $60+ over 5 years.
Interim CFO Richard Johnson will stay in advisory role for smooth transition.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Glenn C. David

Chief Financial Officer

PAHC · PHIBRO ANIMAL HEALTH CORP

Effective: 2024-02-09
Filed: February 6, 2024, 6:59 PM ET

Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024

Role change (interim)

Richard Johnson

interim Chief Financial Officer

PAHC · PHIBRO ANIMAL HEALTH CORP

Effective: 2024-02-09
Successor: Glenn C. David
Filed: February 6, 2024, 6:59 PM ET

Mr. Richard Johnson, who has served as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Glenn C. David was appointed as Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Johnson changed role as interim Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.

Action: stepped down as interim CFO
Role: interim Chief Financial Officer

Exact text from the filing

Mr. Richard Johnson, who has served as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David.

View on SEC.gov

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001104659-24-010954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.